Target intelligence / Profile preview

Necdin, MAGE family member (NDN)

Target
NDN
Molecular classification
Transcription factor, Melanoma antigen (MAGE) family protein, Other (growth suppressor, imprinted gene product)
01

Overview

Necdin, encoded by the **NDN** gene, is a member of the melanoma antigen (MAGE) protein family, located in the Prader-Willi syndrome (PWS) chromosomal region 15q11–q13, and expressed exclusively from the paternal allele due to genomic imprinting[1][2][4][5]. Necdin is primarily expressed in postmitotic neurons and regulates neuronal differentiation, promotes cell survival, and suppresses both cellular proliferation and apoptosis[1][2][3][4][6]. It functions as a transcription factor, binding specific DNA sequences and modulating transcriptional activity, and interacts with regulatory proteins such as E2F1, p53, neurotrophin receptors, and others, integrating complex networks governing neuronal vitality[3][4]. Loss of necdin expression is implicated in Prader-Willi syndrome and neurodevelopmental abnormalities, with reduced expression also associated with increased proliferation and metastasis in various cancers, indicating a tumor suppressor role[2][3][4]. No currently approved drugs target necdin directly, and there are no established safety issues or direct pharmacological interventions related to this protein.

Other names
NecdinNDNHsT16328PWCRPrader-Willi syndrome chromosome regionnecdin homolognecdin, melanoma antigen (MAGE) family membernecdin-like protein
02

Mechanism of action

Not applicable, as no direct drug targeting reported

03

Biological functions

Transcriptional regulationCell cycle arrestSuppression of cellular proliferationPromotion of neuronal differentiation and survivalNeuroprotectionRegulation of apoptosisCell growth regulation
04

Disease associations

Prader-Willi syndrome (neurodevelopmental, imprinting disorder)Schaaf-Yang syndromeCancer (tumor suppressor, role in various carcinomas)Other neurodevelopmental disorders
05

Safety considerations

No notable safety concerns as a therapeutic target; not currently targeted by drugs
06

Interacting drugs

None identified in current knowledge or referenced sources
07

Biomarkers

Loss of NDN expression as a biomarker in cancers for tumor progression/metastasis risk[2][3]Loss of function in Prader-Willi syndrome (as a component of genetic diagnosis)[5]

Beyond the preview

Go deeper on Necdin, MAGE family member (NDN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Necdin, MAGE family member (NDN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call